Jefferies Remains Sidelined on Karyopharm Therapeutics (KPTI) Following 4Q - PT to $10
Tweet Send to a Friend
Jefferies reiterated a Hold rating on Karyopharm Therapeutics (NASDAQ: KPTI), and cut the price target to $10.00 (from $14.00), following ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
